A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) Versus Bupivacaine Alone in Subjects Undergoing Elective Cesarean Section

Trial Profile

A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) Versus Bupivacaine Alone in Subjects Undergoing Elective Cesarean Section

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 May 2018

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Pacira Pharmaceuticals
  • Most Recent Events

    • 01 May 2018 Planned End Date changed from 1 Jun 2018 to 30 Nov 2018.
    • 01 May 2018 Planned primary completion date changed from 1 Feb 2018 to 31 Aug 2018.
    • 28 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top